Pharma BD Deal Intelligence
A $450M all-cash deal that gave Cephalon full worldwide control of Provigil (modafinil), turning it into a $1B+ blockbuster driving over half the company's revenue — but defending that franchise triggered a $1.2B pay-for-delay antitrust settlement, and Cephalon itself was sold to Teva for $6.8B a decade later.
Lafon delivered exactly what Cephalon bought it for — full control of Provigil, which became a $1B+ blockbuster — but Cephalon's subsequent scramble to protect that franchise from generics triggered a $1.2B antitrust settlement, and the whole company (with this asset as centerpiece) was sold to Teva a decade later.
Full analysis, sources & comparables →The acquisition will increase product sales for Cephalon, significantly improve gross margins for PROVIGIL by eliminating payments to Lafon, improve…
US biopharmaceutical company Cephalon has signed an agreement to acquire France's Group Lafon for $450 million in cash. The deal is expected to close by the…
Cephalon obtained modafinil rights from Lafon and grew Provigil to nearly $1B in sales by 2008; Teva later acquired Cephalon in 2011 for $6.8B.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
$450M cash. Acquired worldwide rights to Provigil (modafinil) plus Mitry-Mory mfg facility. Closed 2001-12-28.
Lafon delivered exactly what Cephalon bought it for — full control of Provigil, which became a $1B+ blockbuster — but Cephalon's subsequent scramble to protect that franchise from generics triggered a $1.2B antitrust settlement, and the whole company (with this asset as centerpiece) was sold to Teva a decade later.
Assessment window: 15yr post-close.
Narcolepsy is a chronic neurological disorder of sleep-wake regulation marked by excessive daytime sleepiness and, in some patients, cataplexy. It affects roughly 1 in 2,000 Americans, with substantial diagnostic delay (often ~10 years), and meaningfully impairs driving safety, education, and employment.
At the time of the December 2001 Cephalon-Lafon deal, Provigil (modafinil) — FDA-approved in 1998 for narcolepsy — was the dominant non-amphetamine wake-promoting agent and Cephalon's growth engine. Competing wakefulness therapies were largely older Schedule II stimulants (methylphenidate, dextroamphetamine), with Jazz Pharmaceuticals' Xyrem (sodium oxybate) approved in July 2002 for cataplexy, expanding the category. Modafinil's atypical dopamine reuptake inhibition profile and lower abuse liability differentiated it. By acquiring Group Lafon outright for $450M cash, Cephalon eliminated royalty obligations, captured the Mitry-Mory active substance manufacturing facility, and reduced Provigil cost-of-goods from ~22% to ~7% of sales, per Robertson Stephens analyst Michael King's commentary (BioWorld). The deal also gave Cephalon European commercial infrastructure plus Lafon's local franchise (Spasfon, Fonzylane, Olmifon). Strategically, it set up Cephalon's eventual armodafinil (Nuvigil) lifecycle play and positioned the franchise to absorb the 2003 OSA and shift work disorder label expansions. Generic modafinil only entered the US in 2012 after extensive patent litigation, with Teva acquiring Cephalon in 2011 for $6.8B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Group Lafon (France) (this deal) | 2001 | $450M | 80 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2001 deals · Cephalon Inc. deals